4,544 Shares in Illumina, Inc. $ILMN Bought by Pure Financial Advisors LLC

Pure Financial Advisors LLC acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the second quarter, HoldingsChannel.com reports. The firm acquired 4,544 shares of the life sciences company’s stock, valued at approximately $434,000.

A number of other large investors also recently modified their holdings of ILMN. Rise Advisors LLC boosted its stake in shares of Illumina by 173.6% during the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company’s stock worth $28,000 after buying an additional 224 shares during the last quarter. Rakuten Securities Inc. boosted its stake in shares of Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares during the last quarter. Center for Financial Planning Inc. acquired a new position in shares of Illumina during the 1st quarter worth about $33,000. PFS Partners LLC boosted its stake in shares of Illumina by 400.0% during the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock worth $40,000 after buying an additional 400 shares during the last quarter. Finally, Golden State Wealth Management LLC boosted its stake in shares of Illumina by 123.2% during the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock worth $42,000 after buying an additional 292 shares during the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Stock Up 2.8%

Shares of ILMN opened at $102.12 on Friday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The firm’s 50 day moving average is $99.07 and its 200-day moving average is $89.85. The stock has a market capitalization of $15.70 billion, a PE ratio of 12.93, a P/E/G ratio of 2.40 and a beta of 1.40. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business’s revenue for the quarter was down 4.8% on a year-over-year basis. During the same period last year, the firm earned $0.36 earnings per share. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Equities research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. Robert W. Baird raised their target price on shares of Illumina from $84.00 to $105.00 and gave the company a “neutral” rating in a research note on Monday, July 28th. Evercore ISI raised their target price on shares of Illumina from $116.00 to $128.00 and gave the company an “outperform” rating in a research note on Tuesday, July 8th. Daiwa America downgraded shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 12th. Royal Bank Of Canada set a $124.00 target price on shares of Illumina in a research note on Tuesday, September 2nd. Finally, Morgan Stanley raised their target price on shares of Illumina from $100.00 to $105.00 and gave the company an “equal weight” rating in a research note on Monday, August 4th. Six research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $123.33.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.